Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study
Crossref DOI link: https://doi.org/10.1186/s13075-015-0835-7
Published Online: 2015-11-11
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Curtis, Jeffrey R.
Sarsour, Khaled
Napalkov, Pavel
Costa, Laurie A.
Schulman, Kathy L.